Table 1

Clinical and pathological characteristics of the patients grouped by TIL density

CD3+ TIL

n = 99

CD8+ TIL

n = 107

CD45RO+ TIL

n = 110

Characteristics

low

high

P-value

low

high

P-value

low

high

P-value


Total number of patients

42 (42.4%)

57 (57.6%)

50 (46.7%)

57 (53.3%)

17 (15.5%)

93 (84.5%)

Gender

0.453

1.0

0.607

male

38 (38.4%)

54 (54.5%)

46 (43.0%)

53 (49.5%)

15 (13.6%)

87 (79.1%)

female

4 (4.0%)

3 (3.0%)

4 (3.7%)

4 (3.7%)

2 (1.8%)

6 (5.5%)

Tumour stage

0.298

0.688

0.353

pT1

15 (15.3%)

26 (26.5%)

20 (18.9%)

25 (23.6%)

6 (5.5%)

42 (38.5%)

pT2

7 (7.1%)

12 (12.2%)

9 (8.5%)

12 (11.3%)

2 (1.8%)

18 (16.5%)

pT3

20 (20.4%)

18 (18.4%)

21 (19.8%)

19 (17.9%)

9 (8.3%)

32 (29.4%)

Lymph node metastasis

0.025

0.440

0.065

pN0

17 (17.3%)

35 (35.7%)

26 (24.5%)

31 (29.2%)

6 (5.5%)

54 (49.5%)

pN1

25 (25.5%)

21 (21.4%)

24 (22.6%)

25 (23.6%)

11 (10.1%)

38 (34.9%)

Distant metastasis

0.212

0.428

0.108

M0

37 (37.8%)

53 (54.1%)

45 (42.5%)

52 (49.1%)

14 (12.8%)

87 (79.8%)

M1

5 (5.1%)

3 (3.1%)

5 (4.7%)

4 (3.8%)

3 (2.8%)

5 (4.6%)

Residual tumour

0.070

0.276

0.125

R0

33 (34.4%)

51 (53.1%)

41 (39.4%)

51 (49.0%)

13 (12.1%)

81 (75.7%)

R1

8 (8.3%)

4 (4.2%)

7 (6.7%)

5 (4.8%)

4 (3.7%)

9 (8.4%)

Grading

0.273

0.696

0.091

G1

0 (0.0%)

2 (2.1%)

2 (1.9%)

1 (1.0%)

0 (0.0%)

5 (4.6%)

G2

17 (17.5%)

27 (27.8%)

20 (19.0%)

26 (24.8%)

4 (3.7%)

42 (38.9%)

G3

25 (25.8%)

26 (26.8%)

27 (25.7%)

29 (27.6%)

13 (12.0%)

44 (40.7%)

UICC classification

0.086

0.776

0.156

I

11 (11.2%)

24 (24.5%)

16 (15.1%)

23 (21.7%)

4 (3.7%)

38 (34.9%)

II

11 (11.2%)

19 (19.4%)

16 (15.1%)

17 (16.0%)

4 (3.7%)

28 (25.7%)

III

15 (15.3%)

10 (10.2%)

14 (13.2%)

12 (11.3%)

6 (5.5%)

21 (19.3%)

IV

5 (5.1%)

3 (3.1%)

4 (3.8%)

4 (3.8%)

3 (2.8%)

5 (4.6%)

Recurrence of disease

0.005

0.209

0.018

No

13 (13.3%)

33 (33.7%)

21 (19.8%)

30 (28.3%)

4 (3.7%)

50 (45.9%)

Yes

29 (29.6%)

23 (23.5%)

28 (26.4%)

27 (25.5%)

13 (11.9%)

42 (38.5%)


Rauser et al. BMC Cancer 2010 10:608   doi:10.1186/1471-2407-10-608

Open Data